Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Healthcare Industry News Can Beyond Air’s $32m lifeline drive profitability and global adoption of LungFit PH? Find out how Beyond Air’s $32 million lifeline could drive profitability and global adoption of its LungFit PH nitric oxide therapy device. bySoujanya RaviNovember 5, 2025